Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by crittergitteron Oct 17, 2012 6:40pm
226 Views
Post# 20495656

Sour Lemons...

Sour Lemons...

Seriously - Hepalink has paid $0.20 + for their 10% stake. The market is trading at $0.145.

 

Granted that dilution has irked the long time holder's of this deal and I get that maybe they have

over-promised and under-delivered in the past, but that is quite a stretch to accuse them of FRAUD.

As a newbie onboard, the fact that a global multinational has expressed such a valid interest and has

stepped up to the plate, tells me that PLI has legs to move higher.

 

But then again, what do I know...am I missing something here ?

Bullboard Posts